ACRS | tickerfilter.com

Fundamental analysis

38%

Profitability 35%

Dept financing 25%

Liquidity 58%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

12.61%

1 Month

-15.72%

3 Months

-43.93%

6 Months

-16.77%

1 Year

9.84%

2 Year

-84.93%

Key data

Stock price

$1.34

P/E Ratio

0.00

DAY RANGE

$1.26 - $1.36

EPS

-$1.71

52 WEEK RANGE

$0.95 - $5.17

52 WEEK CHANGE

$9.84

MARKET CAP

177.149 M

YIELD

N/A

SHARES OUTSTANDING

71.345 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-06-2025

BETA

2.23

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,081,681

AVERAGE 30 VOLUME

$947,921

Company detail

CEO: Neal S. Walker
Region: US
Website: aclaristx.com
Employees: 100
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.

ACRS - Aclaris Therapeutics, Inc.